Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials

Critical Reviews in Food Science and Nutrition

Volumn 57, Issue 4, 2017, Pages 666-676

  Sahebkar, Amirhossein ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cardiovascular disease; dyslipidemia; Flavonoid; polyphenol; systematic review

Indexed keywords

CHOLESTEROL; LIPIDS; LIPOPROTEINS; PHENOLS; RANDOM PROCESSES; REGRESSION ANALYSIS; VEGETABLE OILS;

CARDIO-VASCULAR DISEASE; DYSLIPIDEMIAS; FLAVONOID; POLYPHENOLS; SYSTEMATIC REVIEW;

FLAVONOIDS;

ANTILIPEMIC AGENT; QUERCETIN;

ANIMAL; DIETARY SUPPLEMENT; HUMAN; HYPERLIPIDEMIA; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; DIETARY SUPPLEMENTS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; QUERCETIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85007518338     PISSN: 10408398     EISSN: 15497852     Source Type: Journal    
DOI: 10.1080/10408398.2014.948609     Document Type: Article

References (78)

1. Askari, G., Ghiasvand, R., Feizi, A., Ghanadian, S. M., and Karimian, J., (2012). The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J. Res. Med. Sci. 17:637–641.
2. Assmann, G., (2006). Dyslipidaemia and global cardiovascular risk:Clinical issues. Eur. Heart J. Suppl. 8:F40–F46.
3. Banach, M., Serban, C., Aronow, W. S., Rysz, J., Dragan, S., et al. (2014). Lipid, blood pressure and kidney update 2013. Int. Urol. Nephrol. 6:947–961.
4. Bhaskar, S., Kumar, K. S., Krishnan, K., and Antony, H., (2013). Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition 29:219–229.
5. Boots, A. W., Haenen, G. R. M. M., and Bast, A., (2008). Health effects of quercetin:From antioxidant to nutraceutical. Eur. J. Pharmacol. 585:325–337.
6. Borenstein, M., Hedges, L., Higgins, J., and Rothstein, H. (2005). Comprehensive Meta-analysis Version 2. Biostat, EnglewoodNJ.
7. Casaschi, A., Wang, Q., Dang, K., Richards, A., and Theriault, A., (2002). Intestinal apolipoprotein B secretion is inhibited by the flavonoid quercetin:Potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase. Lipids 37:647–652.
8. Castilla, P., Echarri, R., Dávalos, A., Cerrato, F., Ortega, H., et al. (2006). Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Am. J. Clin. Nutr. 84:252–262.
9. Chopra, M., Fitzsimons, P. E., Strain, J. J., Thurnham, D. I., and Howard, A. N., (2000). Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clin. Chem. 46:1162–1170.
10. Conquer, J. A., Maiani, G., Azzini, E., Raguzzini, A., and Holub, B. J., (1998). Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J. Nutr. 128:593–597.
11. Duval, S., and Tweedie, R., (2000). Trim and fill:A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463.
12. Edwards, R. L., Lyon, T., Litwin, S. E., Rabovski, A., Symons, J. D., and Jalili, T., (2007). Quercetin reduces blood pressure in hypertensive subjects. J. Nutr. 137:2405–2411.
13. Egert, S., Boesch-Saadatmandi, C., Wolffram, S., Rimbach, G., and Müller, M. J., (2010). Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J. Nutr. 140:278–284.
14. Egert, S., Bosy-Westphal, A., Seiberl, J., et al. (2009). Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype:A double-blinded, placebo-controlled cross-over study. Br. J. Nutr. 102:1065–1074.
15. Egert, S., Wolffram, S., Bosy-Westphal, A., Kürbitz, C., Settler, U. et al. (2008). Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J. Nutr. 138:1615–1621.
16. Falcone Ferreyra, M. L., Rius, S. P., and Casati, P., (2012). Flavonoids:Biosynthesis, biological functions, and biotechnological applications. Front. Plant Sci. 3:222.
17. Ferrer, J., Austin, M., Stewart, C. J., and Noel, J., (2008). Structure and function of enzymes involved in the biosynthesis of phenylpropanoids. Plant Physiol. Biochem. 46:356–370.
18. Ferretti, G., Bacchetti, T., and Sahebkar, A., (2015). Effect of statin therapy on paraoxonase-1 status:A systematic review and meta-analysis of 25 clinical trials (2015) Prog. Lipid Res. 60:50–73.
19. Gee, J. M., DuPont, M. S., Day, A. J., Plumb, G. W., Williamson, G., and Johnson, I. T., (2000). Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway. J. Nutr. 130:S2765–S2771.
20. Geleijnse, J. M., Launer, L. J., Van der Kuip, D. A., Hofman, A., and Witteman, J. C., (2002). Inverse association of tea and flavonoid intakes with incident myocardial infarction:The Rotterdam Study. Am. J. Clin. Nutr. 75:880–886.
21. Ghorbani, A., (2013). Phytotherapy for diabetic dyslipidemia:Evidence from clinical trials. Clin. Lipidol. 8:311–319.
22. Glässer, G., Graefe, E. U., Struck, F., Veit, M., and Gebhardt, R., (2002). Comparison of antioxidative capacities and inhibitory effects on cholesterol biosynthesis of quercetin and potential metabolites. Phytomedicine 9:33–40.
23. Gnoni, G. V., Paglialonga, G., and Siculella, L., (2009). Quercetin inhibits fatty acid and triacylglycerol synthesis in rat-liver cells. Eur. J. Clin. Invest. 39:761–768.
24. Golomb, B. A., and Evans, M. A., (2008). Statin adverse effects:A review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs 8:373–418.
25. Graefe, E. U., Derendorf, H., and Veit, M., (1999). Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int. J. Clin. Pharmacol. Ther. 37:219–233.
26. Harper, C. R., and Jacobson, T. A., (2007). The broad spectrum of statin myopathy:From myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 18:401–408.
27. Higgins, J. P. T., Green, S., editors. (2009). Cochrane handbook for systematic reviews of interventions Version 5.0.2. The Cochrane Collboration.
28. Hollman, P. C. H., and Katan, M. B., (1999). Dietary Flavonoid:Intake, health effects and bioavailability. Food Chem. Toxicol. 37:937–942.
29. Hooper, L., Kroon, P. A., Rimm, E. B., Cohn, J. S., Harvey, I., et al. (2008). Flavonoids, flavonoid-rich foods, and cardiovascular risk:A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 88:38–50.
30. Hubbard, G. P., Stevens, J. M., Cicmil, M., et al. (2003). Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J. Thromb. Haemost. 1:1079–1088.
31. Hwang, E. K., (2009). Effect of quercetin supplement on major biochemical parameters in sera of rats fed high fat and high cholesterol diet. J. Veterinary Clin. 26:413–418.
32. Hämäläinen, M., Nieminen, R., Vuorela, P., Heinonen, M., and Moilanen, E., (2007). Anti-inflammatory effects of flavonoids:Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 2007:45673.
33. Igarashi, K., and Ohmuma, M., (1995). Effects of isorhamnetin, rhamnetin, and quercetin on the concentrations of cholesterol and lipoperoxide in the serum and liver and on the blood and liver antioxidative enzyme activities of rats. Biosci. Biotechnol. Biochem. 59:595–601.
34. Juźwiak, S., Wójcicki, J., Mokrzycki, K., Marchlewicz, M., Białecka, M., et al. (2005). Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol. Rep. 57:604–609.
35. Kalogeromitros, D., Makris, M., Chliva, C., Aggelides, X., Kempuraj, D., and Theoharides, T. C., (2008). A quercetin containing supplement reduces niacin-induced flush in humans. Int. J. Immunopathol. Pharmacol. 21:509–514.
36. Kamada, C., da Silva, E. L., Ohnishi-Kameyama, M., Moon, J. H., and Terao, J., (2005). Attenuation of lipid peroxidation and hyperlipidemia by quercetin glucoside in the aorta of high cholesterol-fed rabbit. Free Radic. Res. 39:185–194.
37. Kelly, G. S., (2011). Quercetin. Altern. Med. Rev. 16:172–194.
38. Kelly, G. S., (2011). Quercetin. Monograph. Altern. Med. Rev. 16:172–194.
39. Kleemann, R., Verschuren, L., Morrison, M., et al. (2011). Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218:44–52.
40. Knab, A. M., Shanely, R. A., Henson, D. A., Jin, F., Heinz, S. A., et al. (2011). Influence of quercetin supplementation on disease risk factors in community-dwelling adults. J. Am. Diet Assoc. 111:542–549.
41. Knekt, P., Jarvinen, R., Reunanen, A., and Maatela, J., (1996). Flavonoid intake and coronary mortality in Finland:A cohort study. BMJ 312:478–481.
42. Knekt, P., Kumpulainen, J., Järvinen, R., Rissanen, H., Heliövaara, M., et al. (2002). Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 76:560–568.
43. Lakhanpal, P., and Kumar, D., (2007). Quercetin:A Versatile Flavonoid. Internet J. Med. Update 2:22–37.
44. Lamson, D. W., and Brignall, M. S., (2000). Antioxidants and cancer III:Quercetin. Altern. Med. Rev. 5:196–208.
45. Larson, A. J., Symons, J. D., and Jalili, T., (2012). Therapeutic potential of quercetin to decrease blood pressure:Review of efficacy and mechanisms. Adv. Nutr. 3:39–46.
46. Lee, K. H., Park, E., Lee, H. J., Kim, M. O., Cha, Y. J., et al. (2011). Effects of daily quercetin-rich supplementation on cardiometabolic risks in male smokers. Nutr. Res. Pract. 5:28–33.
47. Loke, W. M., Hodgson, J. M., Proudfoot, J. M., McKinley, A. J., Puddey, I. B., and Croft, K. D., (2008). Pure dietary flavonoids quercetin and (−)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am. J. Clin. Nutr. 88:1018–1025.
48. Mariee, A. D., Abd-Allah, G. M., and El-Beshbishy, H. A., (2012). Protective effect of dietary flavonoid quercetin against lipemic-oxidative hepatic injury in hypercholesterolemic rats. Pharm. Biol. 50:1019–1025.
49. Michalska, M., Gluba, A., Mikhailidis, D. P., et al. (2010). The role of polyphenols in cardiovascular disease. Med. Sci. Monit. 16:RA110–RA119.
50. Michalska-Kasiczak, M., Sahebkar, A., Mikhailidis, D. P., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Kees Hovingh, G., Farnier, M., Moriarty, P. M., Bittner, V. A., Lip, G. Y. H., and Banach, M., (2015). Analysis of vitamin D levels in patients with and without statin-associated myalgia - A systematic review and meta-analysis of 7 studies with 2420 patients. Int. J. Cardiol. 178:111–116.
51. Mohammadi, A., Sahebkar, A., Iranshahi, M., et al. (2013). Effects of supplementation with curcuminoids on dyslipidemia in obese patients:A randomized crossover trial. Phytother. Res. 27:374–379.
52. Moher, D., Liberati, A., Tetzlaff, J., and Altman, D. G., (2009). Preferred reporting items for systematic reviews and meta-analyses:The PRISMA statement. BMJ 339:b2535.
53. Nickel, T., Hanssen, H., Sisic, Z., et al. (2011). Immunoregulatory effects of the flavonol quercetin in vitro and in vivo. Eur. J. Nutr. 50:163–172.
54. Nutrient Data Laboratory, Food Composition Laboratory. (2007). USDA database for the flavonoid content of selected foods. Beltsville Human Nutrition Research Center, Agriculture Research Service, USDA, Beltsville, MD.
55. Pérez-Vizcaíno, F., Ibarra, M., Cogolludo, A. L., et al. (2002). Endothelium-independent vasodilator effects of the flavonoid quercetin and its methylated metabolites in rat conductance and resistance arteries. J. Pharmacol. Exp. Ther. 302:66–72.
56. Pfeuffer, M., Auinger, A., Bley, U., et al. (2013). Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr. Metab. Cardiovasc. Dis. 23:403–409.
57. Rizzo, M., Barylski, M., Rizvi, A. A., Montalto, G., Mikhailidis, D. P., and Banach, M., (2013). Combined dyslipidemia:Should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr. Pharm. Des. 19:3858–3868.
58. Rock, W., Rosenblat, M., Borochov-Neori, H., Volkova, N., Judeinstein, S. et al. (2009). Effects of date (Phoenix dactylifera L., Medjool or Hallawi Variety) consumption by healthy subjects on serum glucose and lipid levels and on serum oxidative status:A pilot study. J. Agric. Food Chem. 57:8010–8017.
59. Romero, M., Jiménez, R., Sánchez, M., et al. (2009). Quercetin inhibits vascular superoxide production induced by endothelin-1:Role of NADPH oxidase, uncoupled eNOS and PK. C. Atherosclerosis 202:58–67.
60. Russo, M., Spagnuolo, C., Tedesco, I., Bilotto, S., and Russo, G. L., (2012). The flavonoid quercetin in disease prevention and therapy:Facts and fancies. Biochem. Pharmacol. 83:6–15.
61. Sahebkar, A., (2013). Does PPARγ(2) Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a Meta-Analysis. DNA Cell Biol. 32:188–198.
62. Sahebkar, A., (2013). Fat lowers fat:Purified phospholipids as emerging therapies for dyslipidemia. Biochim. Biophys. Acta. 1831:887–893.
63. Sahebkar, A., (2013). Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39:197–208.
64. Sahebkar, A., (2014). Curcuminoids for the management of hypertriglyceridaemia. Nat. Rev. Cardiol. 11:123.
65. Sahebkar, A., Chew, G. T., and Watts, G. F., (2014). New peroxisome proliferator-activated receptor agonists:Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin. Pharmacother. 15:493–503.
66. Sahebkar, A., Chew, G., and Watts, G., (2014). Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in Lipids Research. 56:47–66.
67. Sahebkar, A., and Watts, G. F., (2013). New LDL-cholesterol lowering therapies:Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin. Ther. 35:1082–1098.
68. Sahebkar, A., and Watts, G. F., (2014). Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease:Tale of a roller-coaster. Diabetes Obes. Metabol. 16:780–792.
69. Sahebkar, A., and Watts, G. F., (2013). New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias:What can the clinician expect? Cardiovasc. Drugs Ther. 27:559–567.
70. Sahebkar, A., and Watts, G. F., (2014). Managing recalcitrant hypercholesterolemia in patients on current best standard of care:Efficacy and safety of novel pharmacotherapies. Clin. Lipidol. 9:221–233.
71. Sanchez, M., Lodi, F., Vera, R., et al. (2007). Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J. Nutr. 137:910–915.
72. Shanely, R. A., Knab, A. M., Nieman, D. C., Jin, F., McAnulty, S. R., and Landram, M. J., (2010). Quercetin supplementation does not alter antioxidant status in humans. Free Radic. Res. 44:224–231.
73. Talirevic, E., and Jelena, S., (2012). Quercetin in the treatment of dyslipidemia. Med. Arh. 66:87–88.
74. Vita, J. A., (2005). Polyphenols and cardiovascular disease:Effects on endothelial and platelet function. Am. J. Clin. Nutr. 81:292S–297S.
75. Winkel-Shirley, B., (2001). Flavonoid biosynthesis. a colorful model for genetics, biochemistry, cell biology, and biotechnology. Plant Physiol. 126:485–493.
76. Yan, A. T., Yan, R. T., Tan, M., et al. (2006). Contemporary management of dyslipidemia in high-risk patients:Targets still not met. Am. J. Med. 19:676–683.
77. Ying, H. Z., Liu, Y. H., Yu, B., Wang, Z. Y., Zang, J. N., and Yu, C. H., (2013). Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils. Food Chem. Toxicol. 52:53–60.
78. Zahedi, M., Ghiasvand, R., Feizi, A., and Asgari, G. R., (2013). Effects of quercetin supplementation on cardiovascular risk factors and inflammatory biomarkers in patients with type 2 diabetes. J. Isfahan. Med. School. 30:2039–2051.